Complex regions of the human genome remained uncharted, even after researchers sequenced the genome in its entirety. That is, ...

What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.4% in the afternoon ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...

Pacific Biosciences: Boom In Genome Sequencing Technology With 35% Upside Aug. 04, 2021 7:30 AM ET Pacific Biosciences of California, Inc. (PACB) Stock PACB 8 Comments 4 Likes Khaveen Investments ...

Illumina, the dominant maker of DNA sequencing machines, has agreed to purchase smaller rival Pacific Biosciences for $8 a share, or $1.2 billion, in an effort to cement its ownership of cutting ...

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a ...

Pacific Biosciences of California, Inc., a pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT®) Technology, today announced it has launched a new nucleic acid ...

Pacific Biosciences of California, Inc. PACB recently introduced the Sequel IIe System, the next instrument evolution powered by its Single Molecule, Real-Time (SMRT) Sequencing technology.This ...

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes ...

--Pacific Biosciences of California, Inc., a global leader offering a comprehensive view of genomes, transcriptomes, and epigenomes, today announced the availability of HiFi Sequencing and ...

Pacific Biosciences CTO Stephen Turner says that the company can complete that mission within the next five years. With it, a "raw" human sequence could be done in three minutes, reports Bio-IT World.

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to ...